The flag marks the reviewer, not the result

A 510(k) record reads the same way whether a government reviewer or a private organization looked at it first: K-number, applicant, product code, decision date, decision. One field rides along underneath that surface, in the releasable data FDA publishes and in openFDA’s own device clearance fields — a plain Y/N flag marking whether the file was reviewed by an accredited third party before it ever reached an FDA desk. Almost no one queries it, and the decision it sits next to does not change based on its value.

What Section 523 actually hands out

Section 523 of the Food, Drug, and Cosmetic Act — 21 U.S.C. § 360m — lets FDA accredit outside organizations to conduct the primary review of certain premarket notifications and recommend a decision. The program has run under a few names since 1998; FDA’s November 2024 final guidance retired Accredited Persons Program in favor of 510(k) Third Party Review Program, or 3P510k, and replaced the prior March 2020 guidance with it. The statute itself draws the eligibility line, not FDA’s discretion alone: no Class III device, no Class II device intended to be permanently implantable, life-sustaining, or life-supporting, and no Class II device whose 510(k) requires clinical data. FDA has put the remaining population at roughly half of the 510(k)s it receives in a given year — low- and moderate-risk Class I and Class II device types, named by product code on a published eligible-device list.

The review moves. The decision doesn’t

A submitter who routes an eligible device through a 3P510k Review Organization pays that organization directly — FDA charges no separate user fee for the service itself. The review organization works the file against the same review criteria FDA uses, then forwards the submission and its own documented recommendation to FDA. FDA reviews that recommendation and makes the final decision; FDA notifies the review organization, and the review organization notifies the submitter. The clearance letter that results is FDA’s own. Nothing about the finding of substantial equivalence is conditional, provisional, or second-tier because an accredited organization did the first pass — the statute built a review channel, not a lesser grade of clearance. FDA separately tracks and publishes each organization’s performance metrics once it has handled at least five submissions, and keeps a current, public list of which organizations are recognized for which product codes.

The field says who looked at the file first. It was never built to say anything about what they found.

What the record keeps, and what it doesn’t

The trace of that channel that survives into the public record is narrow by design: a Y/N flag, defined in FDA’s file layout for releasable 510(k)s as marking whether the submission was reviewed by a third party, carried the same way into openFDA’s device clearance fields. It answers one question — did a 3P510k Review Organization touch this file — and nothing else. It does not name the organization, does not carry a review-time figure, and does not distinguish a clearance that passed the review organization’s recommendation unchanged from one FDA revised before deciding. Every other field on the record — the K-number, the product code, the decision itself — reads identically regardless of which way the flag points.

Why a portfolio watch doesn’t need to branch on it

FDA Radar’s own 510(k) feed keys a portfolio match to K-number, applicant, product code, and decision — the fields a clearance carries regardless of who reviewed it first. A new competitor clearance in your product code is the same signal whether the flag reads Y or N, because the legal fact underneath it is the same signal: FDA found the device substantially equivalent, on a given date, to a given predicate. The flag matters for a different question entirely — whether your own next submission, if it is eligible, is worth routing through an accredited reviewer at all — and that tradeoff, against a specific review organization’s fee, track record, and your own timeline, is a call for your regulatory team to make on your own file. This is a description of what one field in a public record does and doesn’t carry: regulatory intelligence and method, never regulatory advice about which channel to choose.